| First Author | Gopal A | Year | 2022 |
| Journal | J Exp Med | Volume | 219 |
| Issue | 3 | PubMed ID | 35089323 |
| Mgi Jnum | J:329488 | Mgi Id | MGI:7335933 |
| Doi | 10.1084/jem.20200731 | Citation | Gopal A, et al. (2022) TIRAP drives myelosuppression through an Ifngamma-Hmgb1 axis that disrupts the endothelial niche in mice. J Exp Med 219(3):e20200731 |
| abstractText | Inflammation is associated with bone marrow failure syndromes, but how specific molecules impact the bone marrow microenvironment is not well elucidated. We report a novel role for the miR-145 target, Toll/interleukin-1 receptor domain containing adaptor protein (TIRAP), in driving bone marrow failure. We show that TIRAP is overexpressed in various types of myelodysplastic syndromes (MDS) and suppresses all three major hematopoietic lineages. TIRAP expression promotes up-regulation of Ifngamma, leading to myelosuppression through Ifngamma-Ifngammar-mediated release of the alarmin, Hmgb1, which disrupts the bone marrow endothelial niche. Deletion of Ifngamma blocks Hmgb1 release and is sufficient to reverse the endothelial defect and restore myelopoiesis. Contrary to current dogma, TIRAP-activated Ifngamma-driven bone marrow suppression is independent of T cell function or pyroptosis. In the absence of Ifngamma, TIRAP drives myeloproliferation, implicating Ifngamma in suppressing the transformation of MDS to acute leukemia. These findings reveal novel, noncanonical roles of TIRAP, Hmgb1, and Ifngamma in the bone marrow microenvironment and provide insight into the pathophysiology of preleukemic syndromes. |
